Polpharma's acquisition of part of Bioton has been approved by UOKiK.
Polpharma SA is Polish manufacturer of drugs and active pharmaceutical ingredients. Bioton SA produces mainly pharmaceuticals used for injections, including recombined human insulin and other biotechnological drugs.
Polpharma is acquiring the part of its business relating to Biodacyna, a drug used to treat eye infections.
Polish competition law requires UOKiK to be notified of an intended merger where the combined turnover of the merging parties in the preceding financial year exceeds €1 billion worldwide or €50 million in Poland.
This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to www.law-now.com/law-now/mondaq
Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.
The original publication date for this article was 15/02/2010.